Pimavanserin trial for aggression and social thinking
Treatments studied
Part of Mental health clinical trials.
This Phase 2 trial tests pimavanserin, a medication that may affect brain signals, to see if it can reduce aggression and improve social thinking in people with intermittent explosive disorder (IED) or a history of aggressive behavior. If you qualify, you’ll be screened with medical tests and questionnaires and must meet medication and safety rules to participate.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 21 to 55 and able to sign informed consent.
- You have a DSM-5 diagnosis of intermittent explosive disorder (IED) OR your aggression history score is 12 or higher.
- You’re generally physically healthy based on medical history, exam, and an ECG (heart rhythm test), and if you can become pregnant you must have a negative pregnancy test.
- You have been off anti-psychotic medicines for the past 2 weeks.
- You don’t have certain health or mental health conditions (like bipolar disorder, schizophrenia, or significant intellectual disability) and you don’t currently have severe depression, active suicidal thoughts, or a substance use problem beyond mild.
- You must not be allergic to pimavanserin and cannot currently take opiates or certain pain-threshold medicines; you also need screening to rule out heart rhythm issues (QT interval too prolonged).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how inflammation affects aggression by giving a small amount of a substance that briefly triggers your immune system. You may qualify if you have a diagnosis of Intermittent Explosive Disorder (IED), or if you are a healthy control without current anger issues.
This trial tests if pimavanserin can reduce impulse control disorders like gambling, shopping, hypersexuality, or overeating in people with Parkinson's disease. It aims to help those whose symptoms are moderate but not too severe.
This study tests how a drug that blocks a serotonin receptor affects thinking, memory, and mood. It helps researchers understand the role of serotonin in the brain.
This trial tests if the drug pimavanserin can help reduce rigid or repetitive behaviors in people with autism spectrum disorder. It may be an option if you or your child struggle with these symptoms and want to try a new treatment.
This trial tests whether taking pimavanserin before psilocybin changes the drug's effects in healthy volunteers who have never used psychedelics. It aims to understand how to make psychedelic therapy safer and more predictable.
This Phase 2 trial studies pimavanserin, a medicine meant to improve insomnia, in veterans who also have PTSD. It may help reduce problems with falling asleep, staying asleep, or waking too early that affect daytime functioning.
Hear when a new Intermittent Explosive Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.